The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis

References

• Pels H, Juergens A, Schirgens I, et al. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol. 2010;12:720–724.
   PubMed Web of Science ®Google Scholar
• Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2012;14:368–380.
   PubMed Web of Science ®Google Scholar
• Sasagawa Y, Akai T, Tachibana O, et al. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol. 2015;121:177–183.
   PubMed Web of Science ®Google Scholar
• Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95:1504–1510.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Tsuchida T, Uematsu H, et al. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008;190:W365–W369.
   PubMed Web of Science ®Google Scholar
• Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26:96–105.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121:4740–4748.
   PubMed Web of Science ®Google Scholar
• Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest. 1994;93:424–428.
   PubMed Web of Science ®Google Scholar
• Masood R, Zhang Y, Bond MW, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood. 1995;85:3423–3430.
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7:709–723.
   PubMed Web of Science ®Google Scholar
• Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119:2844–2853.
   PubMed Web of Science ®Google Scholar
• Sasayama T, Tanaka K, Mizowaki T, et al. Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in Primary Central Nervous System Lymphoma (PCNSL). Brain Pathol. 2016;26:479–487.
   PubMed Web of Science ®Google Scholar
• Mizowaki T, Sasayama T, Tanaka K, et al. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma. J Neurooncol. 2015;124:165–174.
   PubMed Web of Science ®Google Scholar
• Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48:3253–3259.
   PubMed Web of Science ®Google Scholar
• Kimura K, Usui Y, Goto H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56:383–389.
   PubMed Web of Science ®Google Scholar
• Fisson S, Ouakrim H, Touitou V, et al. Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. PLoS ONE. 2013;8:e52385.
   PubMed Web of Science ®Google Scholar
• Touitou V, LeHoang P, Bodaghi B. Primary CNS lymphoma. Curr Opin Ophthalmol. 2015;26:526–533.
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Eoli M, Corsini E, et al. Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? Ann Neurol. 2000;47:137–138.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med. 2011;155:529–536.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
   PubMed Web of Science ®Google Scholar
• Nguyen-Them L, Costopoulos M, Tanguy ML, et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer. 2016;61:69–76.
   PubMed Web of Science ®Google Scholar
• Mabray MC, Barajas RF, Villanueva-Meyer JE, et al. The combined performance of ADC, CSF CXC chemokine ligand 13, and CSF interleukin 10 in the diagnosis of central nervous system lymphoma. AJNR Am J Neuroradiol. 2016;37:74–79.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang H, Guan L, et al. Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a meta-analysis of animal models. Oncotarget. 2016;7:61764–61774.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Li D, Wang L, Zhu H, et al. Efficacy of allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: a meta-analysis of prospective studies. PLoS ONE. 2015;10:e0132620.
   PubMed Web of Science ®Google Scholar